{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intramuscular+vaccine&page=12",
    "query": {
      "intervention": "Intramuscular vaccine",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 835,
    "total_pages": 84,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intramuscular+vaccine&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intramuscular+vaccine&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T13:46:24.002Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02543268",
      "title": "A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Ad26.ZEBOV-Batch #1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ad26.ZEBOV-Batch #2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ad26.ZEBOV-Batch #3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA-BN-Filo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Crucell Holland BV",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 329,
      "start_date": "2015-09-21",
      "completion_date": "2016-07-20",
      "has_results": false,
      "last_update_posted_date": "2025-06-22",
      "last_synced_at": "2026-11-15T13:46:24.002Z",
      "location_count": 6,
      "location_summary": "Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Mishawaka",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02543268"
    },
    {
      "nct_id": "NCT04762680",
      "title": "Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3159,
      "start_date": "2021-02-24",
      "completion_date": "2023-06-29",
      "has_results": true,
      "last_update_posted_date": "2025-09-18",
      "last_synced_at": "2026-11-15T13:46:24.002Z",
      "location_count": 30,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04762680"
    },
    {
      "nct_id": "NCT04144179",
      "title": "Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Quadrivalent RIV with H3 strain 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent RIV with H3 strain 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent RIV with H3 strain 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent RIV with H3 strain 4",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent RIV with 2018-2019 NH H3 strain",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "18 Years to 30 Years"
      },
      "enrollment_count": 150,
      "start_date": "2019-11-06",
      "completion_date": "2020-02-24",
      "has_results": false,
      "last_update_posted_date": "2025-07-29",
      "last_synced_at": "2026-11-15T13:46:24.002Z",
      "location_count": 3,
      "location_summary": "Hollywood, Florida • Rochester, New York • North Charleston, South Carolina",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "North Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04144179"
    },
    {
      "nct_id": "NCT04708041",
      "title": "Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Papillomavirus Infections"
      ],
      "interventions": [
        {
          "name": "9vHPV vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "26 Years",
        "sex": "ALL",
        "summary": "9 Years to 26 Years"
      },
      "enrollment_count": 700,
      "start_date": "2021-03-15",
      "completion_date": "2029-10-23",
      "has_results": false,
      "last_update_posted_date": "2025-04-20",
      "last_synced_at": "2026-11-15T13:46:24.002Z",
      "location_count": 14,
      "location_summary": "Daly City, California • Oakland, California • Roseville, California + 10 more",
      "locations": [
        {
          "city": "Daly City",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04708041"
    },
    {
      "nct_id": "NCT00767897",
      "title": "The Impact of the Human Papilloma Virus in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Kidney Disease",
        "Dialysis"
      ],
      "interventions": [
        {
          "name": "Human Papillomavirus Vaccine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "18 Years",
        "sex": "FEMALE",
        "summary": "9 Years to 18 Years · Female only"
      },
      "enrollment_count": 72,
      "start_date": "2011-11",
      "completion_date": "2018-12",
      "has_results": false,
      "last_update_posted_date": "2024-03-29",
      "last_synced_at": "2026-11-15T13:46:24.002Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00767897"
    },
    {
      "nct_id": "NCT01320696",
      "title": "Reverse Genetic H9N2 Influenza Vaccine Study in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Alachua Government Services, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 353,
      "start_date": "2011-03",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2023-02-16",
      "last_synced_at": "2026-11-15T13:46:24.002Z",
      "location_count": 5,
      "location_summary": "Huntsville, Alabama • Melbourne, Florida • Peoria, Illinois + 2 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "South Bend",
          "state": "Indiana"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01320696"
    },
    {
      "nct_id": "NCT07861542",
      "title": "Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-M",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 669,
      "start_date": "2026-10-01",
      "completion_date": "2027-01-27",
      "has_results": false,
      "last_update_posted_date": "2026-11-12",
      "last_synced_at": "2026-11-15T13:46:24.002Z",
      "location_count": 20,
      "location_summary": "Fair Oaks, California • Doral, Florida • Atlanta, Georgia + 16 more",
      "locations": [
        {
          "city": "Fair Oaks",
          "state": "California"
        },
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Melrose Park",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07861542"
    },
    {
      "nct_id": "NCT03341754",
      "title": "Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "D/ChAd63-CA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "D/ChAd63-CAT",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Infectivity Control (IC) Group",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 52,
      "start_date": "2018-09-15",
      "completion_date": "2020-03-23",
      "has_results": false,
      "last_update_posted_date": "2020-05-06",
      "last_synced_at": "2026-11-15T13:46:24.002Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • Silver Spring, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03341754"
    },
    {
      "nct_id": "NCT01165229",
      "title": "Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Herpes Zoster",
        "Herpes Zoster Vaccine"
      ],
      "interventions": [
        {
          "name": "Herpes Zoster Vaccine GSK1437173A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "70 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "70 Years and older"
      },
      "enrollment_count": 14819,
      "start_date": "2010-08-02",
      "completion_date": "2015-07-24",
      "has_results": true,
      "last_update_posted_date": "2020-04-27",
      "last_synced_at": "2026-11-15T13:46:24.002Z",
      "location_count": 43,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01165229"
    },
    {
      "nct_id": "NCT00376090",
      "title": "Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "MVA-CMDR",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 48,
      "start_date": "2005-07",
      "completion_date": "2008-12",
      "has_results": false,
      "last_update_posted_date": "2017-10-16",
      "last_synced_at": "2026-11-15T13:46:24.002Z",
      "location_count": 1,
      "location_summary": "Rockville, Maryland",
      "locations": [
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00376090"
    }
  ]
}